Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Oragenics180 Life SciencesCelsionMonopar TherapeuticsReviva Pharmaceuticals
SymbolNYSEAMERICAN:OGENNASDAQ:ATNFNASDAQ:CLSNNASDAQ:MNPRNASDAQ:RVPH
Price Information
Current Price$0.66$8.08$0.98$5.12$4.05
52 Week RangeHoldN/AHoldBuyN/A
MarketRank™
Overall Score0.60.31.31.50.2
Analysis Score0.00.03.03.50.0
Community Score2.60.02.73.10.0
Dividend Score0.00.00.00.00.0
Ownership Score0.01.70.00.80.8
Earnings & Valuation Score0.60.00.60.00.0
Analyst Ratings
Consensus RecommendationHoldN/AHoldBuyN/A
Consensus Price TargetN/AN/A$4.00$30.00N/A
% Upside from Price TargetN/AN/A307.83% upside485.94% upsideN/A
Trade Information
Market Cap$72.13 million$145.70 million$73.58 million$64.34 million$37.39 million
Beta0.64-0.552.42N/A-0.04
Average Volume21,461,8092,903,07017,208,551253,35830,954
Sales & Book Value
Annual RevenueN/AN/A$500,000.00N/AN/A
Price / SalesN/AN/A147.16N/AN/A
CashflowN/AN/AN/AN/A$0.03 per share
Price / CashN/AN/AN/AN/A122.91
Book Value$0.23 per share$1.12 per share$0.63 per share$1.19 per share$0.60 per share
Price / BookN/AN/A1.56N/AN/A
Profitability
Net Income$-15,570,000.00$-90,000.00$-16,850,000.00$-4,220,000.00$620,000.00
EPS($0.37)N/A($0.91)($0.45)N/A
Trailing P/E RatioN/A0.00N/AN/AN/A
Forward P/E RatioN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-4,315.00%N/AN/A
Return on Equity (ROE)-499.13%-94.05%-104.32%-42.84%-13.34%
Return on Assets (ROA)-178.75%-38.77%-47.65%-40.98%-1.36%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.25%N/A0.28%
Current Ratio9.55%0.18%3.67%29.65%0.05%
Quick Ratio9.55%0.18%3.67%29.65%0.05%
Ownership Information
Institutional Ownership Percentage12.75%7.11%13.73%0.66%64.11%
Insider Ownership Percentage9.90%73.50%20.49%48.40%20.60%
Miscellaneous
Employees7N/A2965
Shares Outstanding109.65 million18.03 million75.02 million12.57 million9.23 million
Next Earnings Date5/21/2021 (Estimated)N/A5/21/2021 (Estimated)5/6/2021 (Estimated)5/3/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableNot OptionableNot Optionable
DateCompanyBrokerageAction
6/2/2020OragenicsHC WainwrightDowngrade
7/16/2020CelsionOppenheimerDowngrade
7/13/2020CelsionDawson JamesDowngrade
7/25/2019CelsionBrookline Capital ManagementReiterated Rating
1/28/2021Monopar TherapeuticsRoth CapitalInitiated Coverage
9/24/2020Monopar TherapeuticsMaxim GroupInitiated Coverage
(Data available from 4/21/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.